Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.
D'Haens, Geert R.; Reinisch, Walter; Lee, Scott D.et al.
[en] BACKGROUND: Patients with Crohn's disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1, is a potential novel CD treatment. OPERA II, a multicenter, open-label, phase 2 extension study, assessed the long-term safety and efficacy of ontamalimab in patients with moderate-to-severe CD. METHODS: Patients had completed 12 weeks of blinded treatment (placebo or ontamalimab at 22.5, 75, or 225 mg subcutaneously) in OPERA (NCT01276509) or had a clinical response to ontamalimab 225 mg in TOSCA (NCT01387594). Participants received ontamalimab at 75 mg every 4 weeks (weeks 0-72), then were followed up every 4 weeks for 24 weeks. One-time dose reduction to 22.5 mg or escalation to 225 mg was permitted at the investigator's discretion. The primary end points were safety and tolerability outcomes. Secondary end points included changes in serum drug and biomarker concentrations. Efficacy end points were exploratory, and used non-responder imputation methods. RESULTS: Overall, 149/268 patients completed the study. The most common adverse event leading to study discontinuation was CD flare (19.8%). Two patients died; neither death was considered to be drug related. No dose reductions occurred; 157 patients had their dose escalated. Inflammatory biomarker concentrations decreased. Serum ontamalimab levels were consistent with known pharmacokinetics. Remission rates (Harvey-Bradshaw Index [HBI] ≤ 5; baseline, 48.1%; week 72, 37.3%) and response rates (baseline [decrease in Crohn's Disease Activity Index ≥ 70 points], 63.1%; week 72 [decrease in HBI ≥ 3], 42.5%) decreased gradually. CONCLUSIONS: Ontamalimab was well tolerated; treatment responses appeared to be sustained over 72 weeks.ClinicalTrials.gov ID: NCT01298492.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
D'Haens, Geert R.
Reinisch, Walter
Lee, Scott D.
Tarabar, Dino
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.
Publication date :
2022
Journal title :
Inflammatory Bowel Diseases
ISSN :
1078-0998
eISSN :
1536-4844
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6:644-653.
Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018; 47:896-905.
Lopetuso LR, Gerardi V, Papa V, et al. Can we predict the efficacy of anti-TNF-alpha agents?. Int J Mol Sci. 2017; 18(9): 1973.
Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol. 2010; 3:239-258.
Nakache M, Berg EL, Streeter PR, Butcher EC. The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes. Nature. 1989; 337:179-181.
Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997; 151:97-110.
Streeter PR, Berg EL, Rouse BT, et al. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988; 331:41-46.
Allavena R, Noy S, Andrews M, Pullen N. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol. 2010; 176:556-562.
Nelson SM, Nguyen TM, McDonald JW, MacDonald JK. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018; 8:CD006097.
Chahin S, Berger JR. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. j Neurovirol. 2015; 21:623-631.
Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006; 59:743-747.
Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018; 17:467-480.
D'Haens G, Vermeire S, Vogelsang H, et al. Effect of PF-00547659 on central nervous system immune surveillance and circulating β7+ T cells in Crohn's disease: report of the TOSCA study. J Crohns Colitis. 2018; 12:188-196.
Vermeire S, Loftus EV Jr, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis. 2017; 11:412-424.
Sandborn WJ, Lee SD, Tarabar D, et al. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2018; 67:1824-1835.
Pullen N, Molloy E, Carter D, et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol. 2009; 157:281-293.
D'Alessio S, Spano S, Palliser D, et al. MAdCAM-1 antagonism with ontamalimab promotes drainage of leukocytes in vitro through the intestinal lymphatic endothelium from patients with inflammatory bowel disease. United Europ Gastr J. 2020; 8(S8):453.
Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut. 2011; 60:1068-1075.
Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390:135-144.
Martin SW, Magnusson MO, Matthews IT, et al. Mechanistic population pharmacokinetics (PK) model of PF-00547659, a fully human IgG2 anti-MAdCAM antibody, in ulcerative colitis patients: results of a first in human (Fih) study. Gastroenterology. 2009; 136:A641.
Fernandez Ocana M, Zhang J, Jones B, et al. Validation of assay for detection of free soluble mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in human serum and cerebrospinal fluid. J Crohn's Colitis. 2019; 13(Suppl 1):S119.
Wang Q, Goetsch M. An electrochemiluminescence (ECL) immunoassay for the detection of anti-drug antibodies against the antimucosal addressin cell adhesion molecule (MAdCAM) monoclonal antibody ontamalimab (SHP647). J Crohn's Colitis. 2019; 13(Suppl 1):S096.
Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010; 8:357-363.
R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing [computer program]. Version 3.4.1 or later. Vienna, Austria: R Foundation for Statistical Computing; 2017.
RStudio, Inc. RStudio: Integrated Development for R [computer program]. Version 1.0.153 or later. Boston, MA: RStudio, Inc; 2015.
Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006; 63:1383-1387.
Frohman EM, Monaco MC, Remington G, et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol. 2014; 71:596-602.
Zohren F, Toutzaris D, Klarner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008; 111:3893-3895.
Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut. 1994; 35:231-235.